Clinical Trials Directory

Trials / Unknown

UnknownNCT00900354

Pharmacokinetics of Dactinomycin in Young Patients With Cancer

Pharmacokinetics of Actinomycin D in Children With Cancer

Status
Unknown
Phase
Study type
Observational
Enrollment
50 (estimated)
Sponsor
Children's Cancer and Leukaemia Group · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving dactinomycin may help doctors learn how dactinomycin works in the body and how patients will respond to treatment. PURPOSE: This laboratory study is evaluating the pharmacokinetics of dactinomycin in young patients with cancer.

Detailed description

OBJECTIVES: * Determine the pharmacokinetics (PKs) of dactinomycin in pediatric patients with cancer. * Determine the degree of interpatient variation in the PKs of this drug. * Determine the influence of characteristics such as age, tumor type, and concurrent therapy on drug PKs in these patients. * Correlate drug PKs with clinical response and toxicity observed in these patients, focusing particularly on the incidence of severe liver toxicity or veno-occlusive disease. * Correlate pharmacogenetic variability with clinical and PK data. OUTLINE: This is a multicenter study. Patients undergo blood collection for pharmacokinetic sampling of dactinomycin at baseline (prior to the initiation of dactinomycin) and periodically during course 1 of chemotherapy. An additional blood sample is obtained before or after treatment for the collection of peripheral blood lymphocytes. DNA from these cells is isolated and investigated for genetic variation in genes relevant to the pharmacology of dactinomycin. Plasma concentrations of dactinomycin are determined by liquid chromatography mass spectrometry analysis. Patients are followed for 2 years. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
GENETICmolecular genetic technique
OTHERmass spectrometry
OTHERpharmacological study

Timeline

Start date
2006-06-01
First posted
2009-05-12
Last updated
2013-08-12

Locations

22 sites across 2 countries: Ireland, United Kingdom

Source: ClinicalTrials.gov record NCT00900354. Inclusion in this directory is not an endorsement.